Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
Dated clinical, regulatory and corporate events for Roche Holding AG
How RHHBY actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-15 | Enspryng (satralizumab) | PDUFA Date Approved | PDUFA |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Enicepatide PeptidesNCT07351058 | Obesity or Overweight | Phase 3 | RECRUITING | 3,600 | Aug 7, 2028 | ||||||
| Enicepatide PeptidesNCT07889648 | Type 2 Diabetes Mellitus | Phase 3 | NOT YET_RECRUITING | 948 | Apr 23, 2029 | ||||||
| Enicepatide PeptidesNCT07918846 | Overweight | Phase 3 | NOT YET_RECRUITING | 8,200 | Apr 17, 2031 | ||||||
| Tifeglipron Small MoleculesNCT07112872 | Type 2 Diabetes Mellitus | Phase 2 | RECRUITING | 330 | Feb 5, 2028 | ||||||
| RO7795081 Small MoleculesNCT06982131 | Overweight | Phase 1 | ACTIVE NOT_RECRUITING | 40 | Dec 7, 2026 | ||||||
| RO7795081 Small MoleculesNCT07499050 | Overweight or Obesity | Phase 1 | ACTIVE NOT_RECRUITING | 30 | Jan 9, 2027 | ||||||
| RO7795081 Small MoleculesNCT07741604 | Renal Impairment | Phase 1 | RECRUITING | 60 | Feb 1, 2028 | ||||||
| Fenebrutinib Small MoleculesNCT07937852 | Multiple Sclerosis | Phase 3 | NOT YET_RECRUITING | 1,800 | Nov 30, 2029 | ||||||
| Fenebrutinib Small MoleculesNCT04544449 | Multiple Sclerosis, Primary Progressive | Phase 3 | ACTIVE NOT_RECRUITING | 985 | Jul 21, 2027 | ||||||
| Fenebrutinib Small MoleculesNCT05119569 | Relapsing Multiple Sclerosis | Phase 3 | ACTIVE NOT_RECRUITING | 1,618 | Jun 30, 2027 | ||||||
| Divarasib Small MoleculesNCT04449874 | Non-Small Cell Lung Cancer | Phase 3 | ACTIVE NOT_RECRUITING | 2,156 | Dec 31, 2027 | ||||||
| Giredestrant Small MoleculesNCT04576455 | Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer | Phase 3 | ACTIVE NOT_RECRUITING | 1,295 | Aug 25, 2027 | ||||||
| Giredestrant Small MoleculesNCT04961996 | Early Breast Cancer | Phase 3 | ACTIVE NOT_RECRUITING | 6,191 | Sep 30, 2033 | ||||||
| Giredestrant Small MoleculesNCT05306340 | Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer | Phase 3 | ACTIVE NOT_RECRUITING | 373 | Jun 15, 2027 | ||||||
| Giredestrant Small MoleculesNCT06065748 | Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer | Phase 3 | ACTIVE NOT_RECRUITING | 1,050 | Feb 12, 2029 | ||||||
| Giredestrant Small MoleculesNCT04802759 | Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer | Phase 1/2 | RECRUITING | 316 | May 30, 2029 | ||||||
| Giredestrant Small MoleculesNCT03332797 | Breast Cancer | Phase 1 | ACTIVE NOT_RECRUITING | 256 | Jul 31, 2027 | ||||||
| Cevostamab BiologicsNCT06934044 | Multiple Myeloma | Phase 3 | ACTIVE NOT_RECRUITING | 1,366 | Nov 15, 2028 | ||||||
| Cevostamab BiologicsNCT07629583 | Lupus Erythematosus, Systemic | Phase 1 | RECRUITING | 46 | Mar 29, 2030 | ||||||
| Cevostamab BiologicsNCT05927571 | Relapsed or Refractory Multiple Myeloma | Phase 1 | RECRUITING | 120 | Jul 31, 2027 | ||||||
| Ipatasertib Small MoleculesNCT04931342 | Ovarian Cancer | Phase 2 | ACTIVE NOT_RECRUITING | 176 | May 30, 2028 | ||||||
| Astegolimab BiologicsNCT05878769 | Chronic Obstructive Pulmonary Disease | Phase 3 | ACTIVE NOT_RECRUITING | 4,714 | Jun 30, 2027 | ||||||
| RO7204239 Small MoleculesNCT06965413 | Obesity | Phase 2 | ACTIVE NOT_RECRUITING | 285 | Mar 31, 2027 | ||||||
| RO7204239 Small MoleculesNCT07137585 | Type 2 Diabetes Mellitus | Phase 1 | ACTIVE NOT_RECRUITING | 30 | Feb 28, 2027 | ||||||
| Sefaxersen RNA-Based TherapiesNCT05797610 | Primary IgA Nephropathy | Phase 3 | ACTIVE NOT_RECRUITING | 459 | Aug 31, 2029 |
Readouts, endpoints and source filings for every RHHBY program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| No insider trades match the selected filters. | |||||
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Sofinnova Investments, Inc. | 4.1 % | 70.76 M | 1.37 M |
Shares sold short, counted twice a month.
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
How RHHBY ranks across every disease it competes in